Understanding how Chlamydia trachomatis avoids the immune system
Chlamydia trachomatis evades a novel IL32-mediated immune resistance program
['FUNDING_FELLOWSHIP'] · DUKE UNIVERSITY · NIH-11068680
This study is looking at how the Chlamydia bacteria can hide from our immune system, focusing on a specific gene that helps it do this, with the hope of finding better ways to prevent and treat Chlamydia infections.
Quick facts
| Phase | ['FUNDING_FELLOWSHIP'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | DUKE UNIVERSITY (nih funded) |
| Locations | 1 site (DURHAM, UNITED STATES) |
| Trial ID | NIH-11068680 on ClinicalTrials.gov |
What this research studies
This research investigates the mechanisms by which Chlamydia trachomatis, a common sexually transmitted bacterium, evades the human immune response. The study focuses on a specific gene, IncS, that helps Chlamydia resist immune defenses triggered by interferon-gamma. By examining how this gene functions within infected cells, the research aims to uncover new insights that could lead to better prevention strategies for Chlamydia infections. The findings could ultimately contribute to the development of a vaccine or improved treatments for those affected.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are at risk of Chlamydia infections, particularly sexually active individuals.
Not a fit: Patients who are not sexually active or those who have already been effectively treated for Chlamydia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new strategies for preventing Chlamydia infections and their severe complications, such as infertility.
How similar studies have performed: Previous research has shown promise in understanding immune evasion by pathogens, but this specific approach to studying Chlamydia trachomatis is relatively novel.
Where this research is happening
DURHAM, UNITED STATES
- DUKE UNIVERSITY — DURHAM, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: REITANO, JEFFREY R — DUKE UNIVERSITY
- Study coordinator: REITANO, JEFFREY R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.